Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 20, 2019
- Accepted in final form May 28, 2019
- First Published July 19, 2019.
Author Disclosures
- Sinah Engel*,
- Michaela Friedrich*,
- Muthuraman Muthuraman, PhD,
- Falk Steffen,
- Alicia Poplawski, PhD,
- Sergiu Groppa, MD,
- Stefan Bittner, MD,
- Frauke Zipp, MD and
- Felix Luessi, MD
- Sinah Engel*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michaela Friedrich*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Muthuraman Muthuraman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Falk Steffen,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alicia Poplawski, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergiu Groppa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Bittner, MD,
NONE
NONE
S.B. has received honoraria for travel or speaker honoria from Biogen Idec, Merck Serono, Novartis, Roche and Sanofi- Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frauke Zipp, MD and
(1)Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) ONO (7) Genzyme (8) Sanofi-Aventis (9) Octapharma
NONE
(1)Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) ONO (7) Genzyme (8) Sanofi-Aventis (9) Octapharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Teva (2) Merck Serono (3) Novartis (4) Bayer
(1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, PI, 2013-2019
NONE
(1) Progressive MS Alliance, BRAVEinMS (2) Patient-Centered Outcomes Research Institute (PCORI), PRAG-MS
NONE
NONE
NONE
NONE
NONE
NONE
- Felix Luessi, MD
advisory board member for Roche Pharma
NONE
travel grants from Teva Pharma and Merck Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (S.E., M.F., M.M., F.S., S.G., S.B., F.Z., F.L.), Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University, Mainz; and Institute of Medical Biostatistics (A.P.), Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
- Correspondence
Dr. Luessi luessi{at}uni-mainz.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Serum NFL discriminates Parkinson disease from atypical parkinsonismsTainá M. Marques, Anouke van Rumund, Patrick Oeckl et al.Neurology, February 27, 2019 -
Article
High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MSSimon Thebault, Daniel R. Tessier, Hyunwoo Lee et al.Neurology: Neuroimmunology & Neuroinflammation, August 09, 2019 -
Article
Serum neurofilament light chain in behavioral variant frontotemporal dementiaPetra Steinacker, Sarah Anderl-Straub, Janine Diehl-Schmid et al.Neurology, September 12, 2018 -
Article
Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasiasPetra Steinacker, Elisa Semler, Sarah Anderl-Straub et al.Neurology, February 08, 2017